Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jan 1;39(1):109-116.
doi: 10.1097/BCR.0000000000000546.

Impact of Ulinastatin on Outcomes in Acute Burns Patients

Suhas Vidyadhar Abhyankar  1 , Arvind Madhusudan Vartak  1
Affiliations

Impact of Ulinastatin on Outcomes in Acute Burns Patients

Suhas Vidyadhar Abhyankar et al. J Burn Care Res. .

Abstract

Burns is a global health problem with significant morbidity and mortality. Ulinastatin, a serine protease inhibitor, has the potential to improve outcomes in burns. A retrospective comparative case note review analysis was performed to assess the impact of ulinastatin on the outcomes in acute burns patients. Acute burns patients, admitted to Masina hospital, Mumbai, from October 2012 to April 2015, who received ulinastatin, were identified from the hospital records. A similarly sized cohort of patients, admitted before the introduction of ulinastatin, was also identified. Relevant data were obtained from archived patient files. The outcomes, mortality and length of hospital stay, were compared across different groups and subgroups. Data of 97 patients, 48 of whom received ulinastatin (ulinastatin group) and 49 of whom did not (control group), were captured. Patients in ulinastatin group had received ulinastatin 100,000 IU, 8 to 12 hourly, during a mean period of 8.8 days, based on clinical judgment, in addition to standard hospital care. The in-hospital mortality was lower (60.4%) in ulinastatin group compared with control group (75.5%). The difference in mortality was statistically significant (50% vs 77.27%; P = .04) in those with 41 to 80% burnt BSA. Mean length of hospital stay, where shorter duration of hospitalization is usually associated with death, was higher in ulinastatin group compared with the control group. Ulinastatin appears to reduce mortality in acute burns patients, especially in those with intermediate extent (40 to 80%) of burnt BSA. It also appears to delay death in those who ultimately succumbed to their burn injuries.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Survival outcomes in ulinastatin and control groups.
Figure 2.
Figure 2.
Mortality rates in ulinastatin and control groups based on burnt BSA stratification.
See this image and copyright information in PMC

References

    1. The global burden of disease: 2004 update. World Health Organization; 2008. [online]. Available at: http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004updat.... Accessed October 20, 2015.
    1. WHO | Burns. [online]. Available at: http://www.who.int/violence_injury_prevention/other_injury/burns/en/. Accessed October 20, 2015.
    1. Atiyeh B, Masellis A, Conte C. Optimizing burn treatment in developing low- and middle-income countries with limited health care resources (part 1). Ann Burns Fire Disasters 2009;22:121–5. - PMC - PubMed
    1. WHO | Burns. [online]. Available at: http://www.who.int/mediacentre/factsheets/fs365/en/. Accessed October 20, 2015.
    1. Church D, Elsayed S, Reid O, Winston B, Lindsay R. Burn wound infections. Clin Microbiol Rev 2006;19:403–34. - PMC - PubMed